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Abstract: Prostate cancer is one of the most common cancers diagnosed in men in the United States
and the second leading cause of cancer-related deaths worldwide. Since over 60% of prostate cancer
cases occur in men over 65 years of age, and this population will increase steadily in the coming
years, prostate cancer will be a major cancer-related burden in the foreseeable future. Accumulating
data from more recent research suggest that the tumor microenvironment (TME) plays a previously
unrecognized role in every stage of cancer development, including initiation, proliferation, and
metastasis. Prostate cancer is not only diagnosed in the late stages of life, but also progresses
relatively slowly. This makes prostate cancer an ideal model system for exploring the potential of
natural products as cancer prevention and/or treatment reagents because they usually act relatively
slowly compared to most synthetic drugs. Resveratrol (RSV) is a naturally occurring stilbenoid
and possesses strong anti-cancer properties with few adverse effects. Accumulating data from
both in vitro and in vivo experiments indicate that RSV can interfere with prostate cancer initiation
and progression by targeting the TME. Therefore, this review is aimed to summarize the recent
advancement in RSV-inhibited prostate cancer initiation, proliferation, and metastasis as well as
the underlying molecular mechanisms, with particular emphasis on the effect of RSV on TME. This
will not only better our understanding of prostate cancer TMEs, but also pave the way for the
development of RSV as a potential reagent for prostate cancer prevention and/or therapy.
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For men, prostate cancer is the second most common cancer in the world, resulting
in over 350,000 deaths in 2018 [1]. Most prostate cancers are adenocarcinoma, originating
from epithelial cells in the peripheral zone of the prostate [2]. The survival rate for patients
with prostate cancer confined to the primary site is nearly 100% [3]. If left unchecked,
prostate cancer progresses and eventually metastasizes to form new cancers in other tissues
throughout the body. The overwhelming majority of prostate cancer–related deaths occur
due to metastasis, most often to the bone [4]. Since prostate cancer incidence increases
exponentially for men over 65 years, and this population will increase dramatically in the
coming years, prostate cancer is expected to be a big burden both socially and economically
in the foreseeable future [1].
Because of the importance of the androgen/androgen receptor (AR) signaling pathway in prostate cancer initiation and progression [5], most basic and clinical research
has been focused on the androgen/AR axis. Androgens such as testosterone and dihydrotestosterone bind AR in the cytoplasm and the ligand-bound AR is translocated to the
nucleus to interact with AR responsive elements (ARE) and transcriptionally regulate the
expression of AR target genes such as prostate-specific antigen (PSA) [6]. Dysregulation of
the androgen/AR axis can lead to cancer cell proliferation, escaping from apoptosis, and
metastasis [7,8]. Multiple lines of evidence from recent research indicate that, in addition
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to the androgen/AR axis, the tumor microenvironment (TME) plays an indispensable role
in prostate cancer initiation and progression [9,10]. The TME is composed of fibroblasts,
the extracellular matrix (ECM), immune cells, and other factors in the tumor cell’s surroundings [11]. There is constant communication between tumor cells and the TME [12].
Fibroblasts, especially cancer-associated fibroblasts (CAFs), play important roles in each of
the developmental stages of different cancers, including prostate cancer [9,13]. In fact, AR
signaling is not only involved but also plays an important role in TME [14,15], although the
extent of and exact mechanisms involved in AR-mediated changes in TME are still being
elucidated.
Compared to most other cancers, prostate cancer progression is usually much slower,
so the most common approaches taken with early and low-risk prostate cancers are noninvasive active surveillance and watchful waiting [16]. Advanced prostate cancer is treated
with radical prostatectomy, radiotherapy, chemotherapy, and androgen-deprivation therapy (ADT) through physical or chemical castration to repress androgen-induced AR signaling [17]. Although responsive to ADT at the beginning, most prostate cancers become
ADT-resistant over time [18] due to the formation of constitutively active AR variants or the
activation of AR by other factors [9]. For castration-resistant prostate cancer (CRPC) [19],
treatment is usually the combination of traditional ADT and second-line antiandrogen
drugs such as abiraterone acetate, an androgen synthesis inhibitor, or enzalutamide, to
inhibit AR directly [20,21]. Accumulating data demonstrate that resveratrol (RSV), a stilbenoid produced in multiple plants, possesses strong anti-cancer properties [22,23]. By
targeting both AR [24] and the TME [25,26], RSV can induce growth inhibition, cell cycle
arrest, apoptosis, as well as inhibit metastasis of different cancer types, including prostate
cancer [22,27]. More importantly, since RSV has few side effects at therapeutic concentrations, it can be used as a treatment regimen without fear of complications [28]. To pave
the road for the development of RSV as a preventive and/or therapeutic reagent, either by
itself or in combination with other drugs, our review focuses on the effects of RSV on the
TME in prostate cancer initiation, proliferation, and metastasis.
2. RSV Inhibits Prostate Cancer Initiation by Targeting the TME
The exact point at which prostate tissue transitions from normal to cancerous as well
as the underlying molecular mechanisms remain ambiguous. However, multiple factors,
including the TME, play important roles in the initiation of tumors, including those in the
prostate. Although different components of the TME have their roles in cancer development,
the communication between the prostate stromal and epithelial cells plays an indispensable
role in prostate cancer initiation. Results from research using a mouse model to study
cancer initiation in submandibular glands indicate that the interaction between stroma and
epithelium is essential because malignancy only occurred when stromal and epithelial cells
grew together [29]. Following suit, Chung et al. demonstrated the essentiality of stromal
cells in prostate cancer initiation [30]. Since transitional carcinoma cells from mice bladder
can grow together with embryonic urogenital sinus mesenchyme (UGM), UGM was used
to mimic the reactive human prostate stroma to induce prostatic neoplasms. These results
indicate that crosstalk between the stromal and epithelial cells not only exists but also is
imperative for the initiation of prostate neoplasia. However, since humans have a much
higher proportion of smooth muscle and overall stromal cells than mice [31], this difference
needs to be taken into consideration for any solid conclusions about the role of stroma in
prostate cancer initiation. Therefore, similar studies in humans will be an important step
for an accurate depiction of reactive stroma in prostate cancer initiation.
The development of prostate cancer is very similar to the development of benign
prostate hyperplasia (BPH) because they share similarities at the molecular, cellular, genetic, hormonal, and inflammatory levels [32]. Therefore, studying the initiation of benign
prostate hyperplasia may also provide insight into prostate cancer initiation. Hayward
et al. performed a tissue recombination study by co-culturing benign prostate epithelial
cells with stromal cells from either BPH or normal prostate tissues [33] and found that sig-
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nificant epithelial proliferation occurred only when co-cultured with BPH stromal cell lines,
indicating that stromal cells have an important role in BPH development. It is important
to note that although stromal cells can influence the development of malignancy [34], the
communication between the stroma and epithelium is bidirectional. Epithelium-derived
cancer cells are capable of influencing the stroma, specifically that of the smooth muscle.
Co-culturing of 18-day embryonic rat UGM tissue with either normal epithelial cells or
neoplastic prostate epithelial cells showed that the cells from the normal epithelia induce
ductal structure formation in smooth muscle, while the cells from neoplastic prostate
epithelia failed to do so [33]. These findings altogether indicate that the stromal cells play
an important role in prostate cancer initiation, and malignant cells are capable of affecting
stromal cell behavior. Given the importance of stroma–epithelium crosstalk in prostate
cancer initiation, interrupting this communication could be a plausible strategy in the
prevention of prostate cancer initiation [35].
Although multiple lines of evidence indicate that stroma–epithelium crosstalk is
essential in the initiation of prostate cancer, the exact role of stromal cells in prostate cancer
initiation is currently unknown. Based on the fact that the stromal cells in non-cancerous
tissues are more stable than in cancerous tissues, it has been postulated that it is the cancerassociated fibroblasts (CAFs), not the normal stromal cells, that induce tumor initiation [35].
Cunah et al. engrafted BPH-1 cells with either normal stroma or CAFs to adult male mice
and found that tumors formed only when the cells were co-engrafted with CAFs [36].
Therefore, it is hypothesized that the CAFs may secrete excess growth factors and/or
cytokines to protect the tumor cells from apoptotic death and subsequently lead to tumor
formation [37]. As depicted in Figure 1, CAFs secrete more transforming growth factorbeta (TGF-β) than the normal stroma [38]. By activating TGF-β Receptor II (TBRII), the
TGF-β can enhance cell proliferation, differentiation, and extracellular matrix production.
Given that the prostate epithelial cells are TGF-β Receptor II (TBRII)-positive [39], it is
fully conceivable that TGF-β/TBRII can mediate the communication between CAFs and
prostate epithelial cells (Figure 1).
Since the cancer-preventive effects of RSV were first reported in 1997 [22], both epidemiological and case-controlled studies have demonstrated that RSV and/or consumption
of foods/drinks with high levels of RSV can reduce prostate cancer incidence [40]. These
findings suggest that RSV could potentially inhibit prostate cancer initiation. Based on
the role of CAFs in prostate cancer initiation, early research was focused on the effect
of RSV on CAFs. To determine if RSV can inhibit CAF-induced prostate cancer initiation, Wen et al. examined the effect of RSV on TGF-β secretion and found that RSV is
capable of downregulating TGF-β expression from CAFs [8]. Further research demonstrated that the downregulation of TGF-β is partially due to RSV’s repressive effect on
the Wnt/Beta-catenin pathway [41]. Given that the Wnt pathway in prostate epithelial
cells can be activated by CAFs, and RSV is capable of inhibiting TGF-β secretion from
CAFs, RSV is likely to inhibit prostate cancer initiation by targeting the TGF-β/TBRII
axis. Also, activation of the JAK2/pSTAT1 pathway activates mast cells, leading to inflammation and the transition of stroma to CAFs [42]. Since RSV can cause mast cells
to reduce fibrosis by targeting the SCF and c-kit pathway [43], it is also likely that RSV
inhibits prostate cancer initiation through repression of mast cell–mediated stromal cell
transition to CAFs (Figure 1). However, to demonstrate that RSV can inhibit prostate cancer
initiation unambiguously, it is important to conduct both in vitro and in vivo experiments
to demonstrate RSV’s role in inhibiting prostate cell cancerization.
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ventral prostate decreased significantly [51]. The authors also observed that the transgenic
mice had a marked increase (42–62%) of well-differentiated prostate tumors
5 compared to
the control animals, suggesting that RSV can halt tumor progression. Wang, et al. injected
LNCaP cells into mice on an RSV-enriched diet and found that RSV can delay tumor growth.
Of note, both Harper and Wang’s studies suggest that RSV targeted the hormone-based
based signaling pathways [50,51]. However, the RSV-mediated delay was only temposignaling pathways [50,51]. However, the RSV-mediated delay was only temporary, as
rary, as the tumor volumes of the xenograft mice fed RSV eventually caught up with those
the tumor volumes of the xenograft mice fed RSV eventually caught up with those of the
of the controls. The underlying mechanisms remain unknown.
controls. The underlying mechanisms remain unknown.
Increased levels of interleukin-6 (IL-6) have been linked to poor survival among prosIncreased levels of interleukin-6 (IL-6) have been linked to poor survival among
tate cancer patients, and it is known that CAFs secrete high levels of IL-6 into the TME.
prostate cancer patients, and it is known that CAFs secrete high levels of IL-6 into the
One of the signaling pathways activated by IL-6 is JAK/STAT3. Activation of this pathway
TME. One of the signaling pathways activated by IL-6 is JAK/STAT3. Activation of
in the cells leads to tumor cell proliferation and escape from apoptosis. Mechanistically,
this pathway in the cells leads to tumor cell proliferation and escape from apoptosis.
the IL-6-activated JAK leads to STAT3 dimerization and translocation to the nucleus to
Mechanistically, the IL-6-activated JAK leads to STAT3 dimerization and translocation
upregulate theto
expression
of proliferative
proteins
like Bcl-xof
and
Mcl-1 [52,53].
These like
anti-Bcl-x and Mclthe nucleus
to upregulate
the expression
proliferative
proteins
apoptotic proteins
collectively
(Figure 2) prevent
cell
death by(Figure
reducing
mitochondrial
1 [52,53].
These anti-apoptotic
proteins
collectively
2) prevent
cell death by reducing
outer membrane
permeability
[54].
When
LNCAP
and
22RV1
cells
were
treated
mitochondrial outer membrane permeability [54]. When LNCAPwith
and IL22RV1 cells were
6, the STAT3 was
phosphorylated
andSTAT3
activated
accompaniedand
by enhanced
treated
with IL-6, the
was[55],
phosphorylated
activated cell
[55],proaccompanied by
liferation. Consistently,
of the Consistently,
IL-6/STAT3 signaling
pathway
is proportional
enhanced the
cellactivity
proliferation.
the activity
of the IL-6/STAT3
signaling pathway
to the growth rate
of advanced
prostate
cancer
[56].
Additionally,
has been
that
is proportional
to the
growth
rate of
advanced
prostateitcancer
[56].found
Additionally,
it has been
in LNCAP cellsfound
the IL-6-activated
JAK/STAT3
pathway also JAK/STAT3
downregulates
p53, a major
that in LNCAP
cells the IL-6-activated
pathway
also downregulates
cell cycle regulator
lines
of evidence
indicate
that the
CAF-secreted
p53, [57,58].
a majorMultiple
cell cycle
regulator
[57,58].
Multiple
lines
of evidenceIL-6
indicate that the
may also influence
tumor
growth
by
affecting
AR
activity.
Hobisch
et
al.
first observed
CAF-secreted IL-6 may also influence tumor growth by affecting
AR activity. Hobisch
that in prostateetcancer
IL-6 can
activate
AR in
a dose-dependent
[59].inSoon
al. firstcells
observed
that
in prostate
cancer
cells IL-6 can manner
activate AR
a dose-dependent
after, it was found
that [59].
in LNCaP
kinase
Pim1
manner
Sooncells
after,the
it IL-6-upregulated
was found that inserine-threonine
LNCaP cells the
IL-6-upregulated
serinecan phosphorylate
(serine-213)
and can
activate
AR [60,61].
In addition,
al. In addition,
threonine
kinase Pim1
phosphorylate
(serine-213)
and Kemskova
activate AR et
[60,61].
demonstrated Kemskova
that Pim1 isetalso
regulated by STAT3.
These
findings
altogether
indicateThese findings
al. demonstrated
that Pim1
is also
regulated
by STAT3.
that the IL-6/JAK/STAT3
can enhance
prostate cancerpathway
cell proliferation
in anprostate
ARaltogether pathway
indicate that
the IL-6/JAK/STAT3
can enhance
cancer cell
dependent manner
[62]
(Figure
2).
Therefore,
monoclonal
and
immunotherapeutic
treatproliferation in an AR-dependent manner [62] (Figure 2). Therefore, monoclonal and
ments targeting
the IL-6/JAK/STAT3treatments
pathway are
currently
vigorous investigation
immunotherapeutic
targeting
theunder
IL-6/JAK/STAT3
pathway are currently
[55,63].
under vigorous investigation [55,63].

iot. 2021, 2, FOR PEER REVIEW

Figure 2. RSV
inhibits
prostate
cancer
proliferation.
Hypoxia-induced
HIF1α andHIF1α
activation
of JAK/STAT
Figure
2. RSV
inhibits
prostate
cancer proliferation.
Hypoxia-induced
and activation
of by the CAFsJAK/STAT
by thegrowth,
CAFs- secreted
enhance
growth,
and RSV is capable of inhibiting cell
secreted IL-6
enhance tumor
and RSVIL-6
is capable
oftumor
inhibiting
cell proliferation.
proliferation.

It has been reported that RSV can exert a strong anti-proliferative and pro-apoptosis
effect
on the
CAFs
both
prostate
andanti-proliferative
lung cancer cell lines
Meanwhile, RSV blunts
It has been reported
that
RSVincan
exert
a strong
and [64].
pro-apoptosis
and in
even
reverses
phenoconversion
normal
prostate
fibroblast
myofibroblast. RSV
effect on the CAFs
both
prostate
and lung cancerfrom
cell lines
[64].
Meanwhile,
RSVtoblunts
and even reverses phenoconversion from normal prostate fibroblast to myofibroblast.
RSV also indirectly affects IL-6 signaling by inhibiting its downstream factor STAT3 to
mitigate proliferative effects. For example, experimental results from mouse fibroblast
(NIH3T3) cells and LNCaP cells showed the inhibitory effect of RSV on Src tyrosine ki-

J. Xenobiot. 2021, 11

21

also indirectly affects IL-6 signaling by inhibiting its downstream factor STAT3 to mitigate
proliferative effects. For example, experimental results from mouse fibroblast (NIH3T3) cells
and LNCaP cells showed the inhibitory effect of RSV on Src tyrosine kinase, an activator
of STAT3, repressing the STAT3 signaling pathway [65,66] and subsequently reducing cell
growth and increasing apoptosis (Figure 2). The authors posit that apoptosis is triggered by
downregulating downstream factors like Bcl-x, Mcl-, and Cyclin D1 [67,68]. Furthermore,
Lee et al. demonstrated that inhibiting IL-6 RSV can repress STAT3-upregulated AR and cell
proliferation in prostate cancer cells [25].
3.2. RSV Inhibits Cancer Cell Proliferation by Affecting Hypoxic Conditions of the TME
It is well established that aerobic glycolysis, also known as the Warburg effect, occurs
in cells of solid tumors. Hypoxia and high acidity are the two main characteristics of
the Warburg effect, and both of them favor the proliferation of cells in solid cancer [69].
Numerous signaling pathways in prostate cancer cells respond to the hypoxic TME, and
these pathways collectively lead to increased angiogenesis, survival, proliferation, and/or
metastasis [70]. Hypoxia-inducible factor 1-α (HIF1α) plays a central role in cellular
adaptation to hypoxic conditions. In hypoxia, the stabilized HIF1α transcriptionally
regulates the pro-proliferative and anti-apoptotic genes [71]. Meanwhile, O2 is more
frequently reduced to reactive oxygen species (ROS), such as superoxide (O2 − ) [72,73],
which can further stabilize HIF1α [74,75]. Understanding the mechanisms by which tumor
cells proliferate in response to the hypoxic TME may prove advantageous for targeted
inhibition of cancer cell proliferation.
RSV appears to be both pro- and anti-oxidant, depending on the circumstances [76].
In non-cancer tissues, RSV serves as an antioxidant [77], and therefore RSV can exert a
beneficial effect on a wide variety of issues, including neuronal [78], anti-inflammatory [79],
and cardiac [80]. However, to cancer cells with low pH environments due to the Warburg
Effect, RSV shows more pro-oxidant characteristics. Shamim et al. found that RSV can
induce cancer cell death by inducing ROS accumulation, which subsequently leads to
oxidative DNA damage and apoptosis [81–83]. Using the TRAMP model, Wang et al.
demonstrated that RSV-enhanced cancer cell death is due to the upregulation of HIF1α,
which enhances ROS concentration in the TME beyond the limit for survival [84]. Since RSV
preferentially increases superoxide over other ROS species like hydrogen peroxide [85],
Low et al. expounded on the pro-apoptotic effects of elevated superoxide levels in the
mitochondria [86] and found that superoxide can activate caspases 9 and 3, and subsequently promote the release of cytochrome C and apoptosis (Figure 2). It is important to
note that low concentration of RSV can serve as a pro-oxidant that favors cell survival,
and pro-apoptotic effects occur only at relatively higher RSV concentrations to stimulate
superoxide production. The bidirectional nature of RSV needs to be considered when RSV
is used as a therapeutic reagent.
4. RSV Inhibits Prostate Cancer Metastasis by Targeting the TME
The migration of cells in solid cancers toward their surrounding tissues is the first
step of metastasis. Migratory cancer cells undergo both molecular and cellular changes in
response to their TME. These changes are collectively known as epithelial-mesenchymal
transition (EMT), in which the epithelial cells lose their cell–cell adhesion and gain migratory and invasive properties. Generally, the stroma in non-cancer tissues is rather stable.
However, both genetic and epigenetic changes have been found in CAFs [87]. Given that
constant communication occurs between stromal cells and cancerous epithelial cells [13],
it is conceivable that CAFs could affect the migratory properties of the cancer cells. Multiple lines of evidence indicate that the CAFs are capable of promoting EMT [30,87] and
consequently enhance cancer cell migration and invasion [88,89]. Therefore, understanding stroma-mediated EMT is of importance not only in understanding the underlying
molecular mechanism but also for identifying potential agents to prevent or even reverse
metastasis [89].

J. Xenobiot. 2021, 11

22

nobiot. 2021, 2, FOR PEER REVIEW

7

4.1. Resveratrol Interrupts the Communication between Stromal and Cancer Cells
One of the effects that CAFs exerted on cancer cells to enhance EMT is to secret difOne of the effects that CAFs exerted on cancer cells to enhance EMT is to secret different factors into the TME, which are subsequently sensed by cancer cells [90]. Indeed,
ferent factors into the TME, which are subsequently sensed by cancer cells [90]. Indeed,
the level of hepatocyte growth factor (HGF) in the TME of metastatic prostate cancer is
the level of hepatocyte growth factor (HGF) in the TME of metastatic prostate cancer is
higher than that of non-metastatic cancers [90]. Glenn A. Gmyrek et al. [91] have experihigher than that of non-metastatic cancers [90]. Glenn A. Gmyrek et al. [91] have experimentally demonstrated that HGF is capable of triggering pro-migratory phosphorylation
mentally demonstrated that HGF is capable of triggering pro-migratory phosphorylation
of prostate cancer cells and enhancing migration and metastasis. The same group of reof prostate cancer cells and enhancing migration and metastasis. The same group of researchers further demonstrated that the cultured stromal cells showed a myofibroblastic
searchers further demonstrated that the cultured stromal cells showed a myofibroblastic
phenotype and speculated that the myofibroblastic subpopulation of prostate stromal cells
phenotype and speculated that the myofibroblastic subpopulation of prostate stromal
could be the source of HGF in vivo [91]. Further analysis found that in prostate tissues the
cells could be the source of HGF in vivo [91]. Further analysis found that in prostate tisis expressed
in the stromal
but epithelium,
not the epithelium,
suggesting
sues the HGF HGF
is expressed
in the stromal
cells butcells
not the
suggesting
the HGF the HGF in the
TME
could
be
the
result
of
paracrine
secretion.
Since
CAFs
secrete
higher
in the TME could be the result of paracrine secretion. Since CAFs secrete higher levels
of levels of HGF
than
normal
stromal
cells,
the
CAFs
were
postulated
as
the
culprits
driving
cancer cell
HGF than normal stromal cells, the CAFs were postulated as the culprits driving cancer
migration
[26,91].
Later,
it
was
experimentally
demonstrated
that
stromal
cells
are
capable
cell migration [26,91]. Later, it was experimentally demonstrated that stromal cells are
of enhancing
prostate
cancer
cell migration
andeffect
that is
this
effect is HGF-dependent [92].
capable of enhancing
prostate
cancer cell
migration
and that this
HGF-dependent
Mechanistically,
the
CAF-derived
HGF
interacts
with
c-Met
[92]. Mechanistically, the CAF-derived HGF interacts with c-Met receptors on receptors
cancer cellson cancer cells to
activate
numerous
signaling
pathways,
especially
those
related
EMT and metastasis [90]
to activate numerous signaling pathways, especially those related to EMT and to
metastasis
(Figure
3).
Therefore,
any
strategies
interrupting
the
HGF/c-Met
interaction by either
[90] (Figure 3). Therefore, any strategies interrupting the HGF/c-Met interaction by either
inhibiting
the
secretion
of
HGF
or
repressing
the
cancer
cell
responses
HGF could inhibit
inhibiting the secretion of HGF or repressing the cancer cell responses to HGF couldtoinEMT
and
metastasis.
To
determine
if
RSV
can
repress
stromal
cell–mediated
hibit EMT and metastasis. To determine if RSV can repress stromal cell–mediated prostate prostate cancer
migration,
Hsieh
TCco-cultured
et al. co-cultured
andcells
cancer
cellspresence
in the presence
or absence
cancer migration,
Hsieh TC
et al.
stromalstromal
and cancer
in the
or
of and
RSVfound
and found
thatcan
RSVindeed
can indeed
stromal
cell–enhanced
absence of RSV
that RSV
inhibitinhibit
stromal
cell–enhanced
cancercancer
cell cell migration.
Since
treatment
co-culture
with
either
RSV
antibodies
specifically against HGF
migration. Since
treatment
of of
thethe
co-culture
with
either
RSV
or or
antibodies
specifically
abolishedstroma-enhanced
stroma-enhancedmigration
migrationtotoa asimilar
similardegree,
degree,the
theauthors
authors
proposed that RSV
against HGF abolished
proinhibits
cancer
cell
migration
byby
counteracting
posed that RSV
inhibits
cancer
cell
migration
counteractingthe
thestromal
stromalcell–derived
cell–derived HGF [92]. These
findings
altogether
indicate
HGFplays
playsimimportant roles in
HGF [92]. These
findings
altogether
indicatethat
that(1)
(1)stromal
stromal cell–secreted
cell–secreted HGF
prostate
cancer
RSVinhibits
inhibitsprostate
prostatecancancer migration at
portant roles in
prostate
cancermigration
migrationand
andinvasion,
invasion, and (2) RSV
partially
byby
counteracting
cer migration least
at least
partially
counteractingHGF
HGF(Figure
(Figure3).
3).

Figure
3. RSV
inhibits
EMT and
cell metastasis.
The CAFs-released
TGF-,
and HGF
Figure 3. RSV
inhibits
EMT
and cancer
cellcancer
metastasis.
The CAFs-released
TGF-β,
VEGFVEGF
and HGF
(A) interact with
(A)
interact
with
their
corresponding
receptors
on
cancer
cells
and
enhance
EMT
processes
(B).
their corresponding receptors on cancer cells and enhance EMT processes (B). The cancer cells metastasize from their
The cancer cells metastasize from their primary site (B) to the bone (C). RSV is capable of inhibitprimary site (B) to the bone (C). RSV is capable of inhibiting prostate cancer metastasis by repressing EMT and cancer cell
ing prostate cancer metastasis by repressing EMT and cancer cell migration/invasion.
migration/invasion.

J. Xenobiot. 2021, 11

23

It is well known that the ion channel transient receptor potential ankyrin 1 (TRPA1)
on CAFs is one of the main control mechanisms for HGF secretion. To further understand
the mechanism of RSV-inhibited cancer migration, both mouse [93] and rat [94] models
were used, and the results demonstrated that RSV can block HGF secretion by inhibiting
TRPA1. Additionally, Vancauwenberghe et al. [26] further demonstrated that by inhibiting
the TRPA1, RSV is capable of blocking the secretion of both HGF and vascular endothelial
growth factor (VEGF), an important factor involving the angiogenesis of tumor tissues.
These findings altogether suggest that RSV could be potentially used as a reagent to inhibit
prostate cancer metastasis (Figure 3). Of note, this same study [89] also noticed that RSV
can exert an opposite effect on cells expressing a mutant TRPA1, which not only increased
expression and secretion of HGF and VEGF, but also enhanced prostate cancer metastasis.
Therefore, it is important to stratify prostate cancer patients based on their TRPA1 types
and apply RSV only to those with wild-type TRPA1.
4.2. Resveratrol Inhibits Prostate Cancer Metastasis by Targeting the Extracellular Matrix
The extracellular matrix (ECM) is a network formed between cells composed of noncellular components such as protein, glycosaminoglycan, and glycoconjugate. The ECM
can provide both structural and biochemical support to the resident cells, and therefore
the ECM can affect cellular behaviors. One of the largest components of the ECM is
collagen, which is synthesized and secreted by fibroblasts located in the stroma [95].
Communication between collagen and cancer cells exists in every cancer development
stage [96]. Additionally, cadherin plays important structural and signaling roles in cell–cell
and cell–ECM interactions [97]. E-cadherin usually maintains the integrity of epithelial
tissue, and N-cadherin mediates the contact between cells and the matrix. During the
EMT process, N-cadherin is usually upregulated with concurrent downregulation of Ecadherin [98]. Combined dysregulations make the tumor cells more motile and favor
metastasis, thereby allowing cancer cells to escape from the site of origin. Therefore, the
ECM is an additional barrier to break before the cancer cells can escape from the TME.
Activation of the PI3K signaling pathway can lead to collagen production and fibrosis [99]. The transforming growth factor beta-1 (TGFβ-1), secreted from human prostate
stromal cells, can reactivate the stroma by stimulating the phenotypic switch of fibroblasts
to myofibroblasts, thus further increasing collagen secretion [95]. It has been shown that
RSV can inhibit both the TGFβ and PI3K signaling pathways, thereby decreasing the
production and secretion of collagen from the stroma. Since collagen is so prevalent in both
benign and malignant tissue, it has been shown that, in organs with highly collagenous
reactive stroma, the structural properties of collagen contribute to tumor invasion and
metastasis [99]. In normal tissue, the collagen production and assembly are regulated by the
counterbalance of matrix metalloproteinase (MMP), MMP inhibitors, and other enzymes.
The collagen in TME affects tumor cells’ proliferation, differentiation, gene expression,
migration, invasion, and metastasis. Since the MMPs in TME are more prevalent, they
degrade and remodel the basement membrane, which favors tumor cell migration and
metastasis [100]. The inhibitory effects of RSV on TGFβ and/or CXCL12-mediated myofibroblast phenoconversion of prostate fibroblasts in vitro [64] in a concentration-dependent
manner have been reported. Since phenoconversion is necessary for increased collagen
production [101], and increased collagen has been shown to contribute to tumor invasion
and metastasis, it is conceivable that RSV might be able to inhibit prostate cell metastasis
by preventing fibroblast to myofibroblast transition (Figure 3).
The stromal-cell–secreted MMPs play an indispensable role in cancer cell metastasis,
with MMP-2 and MMP-9 being the best-studied MMPs in prostate cancer metastasis. In
tissues with non-migrating cells, the MMPs are inhibited by tissue inhibitors of metalloproteinase (TIMPs). However, upregulated expressions of MMP-2 and MMP-9, accompanied
by downregulated TIMPs, were found in high-grade tumors [102], suggesting that interrupting the delicate balance between MMPs and TIMPs could affect tumor cell migration
and cancer metastasis. Once secreted, both MMP-2 and MMP-9 promote metastasis by
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either enhancing the degradation of barriers of the ECM, such as collagen and laminins,
or affecting the balance between cell–cell and cell–matrix attachments [103]. Since the
inhibitory effect of RSV on MMPs has been shown in many cancer types, and RSV is capable of inhibiting both MMP-2 and MMP-9 [102], the inhibitory effect of RSV on prostate
cancer was examined in different models. The results from the animal models indicate
that RSV and the tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL)
can act individually; the combination of them inhibits prostate cancer metastasis synergistically [104]. Also, it has been noted that androgen treatment of the LNCaP cells can
morphologically alter the cells from spindle-like into fibroblast mesenchymal cell shape,
and RSV is capable of inhibiting the androgen-induced morphological change [105]. Since
this kind of morphological change usually occurs during the EMT process, it further implies that RSV may play a role in prostate cancer cell EMT. In addition, it appears that RSV
is also capable of regulating the expression of cadherin. Loh et al. showed that RSV can
restore the epithelial phenotype of the mesenchymal cells and inhibit the expression of
EMT-related markers [106]. Consistently, our unpublished data also support the notion that
RSV can inhibit EMT by up- and downregulating E-cadherin and N-cadherin, respectively,
in prostate cancer cells.
4.3. Inhibitory Effects of RSV on Prostate Cancer Cell Bone Metastasis
Once escaped from their primary sites into the bloodstream, cancer cells can travel
through the blood and resettle in different organs of the body, although prostate cancer cells
preferentially metastasize to the bone. Therefore, metastatic bone cancer is the leading cause
of death for patients with prostate cancer [4]. A better understanding of the communication
between prostate cancer cells and the bone microenvironment is the first step in designing
strategies to prevent bone metastasis of prostate cancer [107].
The CXCR4/CXCL12 axis plays essential roles in all stages of prostate cancer progression [108], including bone metastasis [109]. Interaction between CXCL12 and CXCR4
leads to the activation of multiple downstream pathways such as MAPK and JNK [110]
and ultimately causes cytoskeletal rearrangements, actin polymerization, and integrindependent adhesion to endothelial cells [110]. On the one hand, higher levels of CXCL12
are expressed in bone marrow stromal cells [109]. On the other hand, most prostate cancer
cells express elevated levels of CXCR4, which makes the CXCL12/CXCR4 axis more active
in these cells. Indeed, CXCL12 can enhance the adhesion of prostate cancer cells with
osteosarcoma cells [111]. In addition, Sun et al. compared the levels of CXCL12 in different tissues and found that, in both human and mouse models, the levels of CXCL12 are
higher in the prostate cancer–preferred metastatic tissues than in those rarely targeted [112].
To further demonstrate how essential CXCR4 is to prostate cancer bone metastasis, the
authors neutralized the receptor by injecting antibodies against CXCR4 and found that
prostate-cancer-to-bone metastases were significantly inhibited [112].
Compared to the surrounding non-cancerous tissues, the vascular endothelial growth
factor (VEGF) is upregulated in most solid cancers, including prostate cancer, and one of
the major sources of VEGF in the TME is CAFs [113]. Consistently, overexpression of VEGF
receptors (VEGFR) has been found in cancerous endothelial cells, which play an indispensable role in cancer cell migration and metastasis [114]. More recent results indicate that the
interaction between the tumor and stromal cells can further induce HIF1α-mediated VEGF
secretion from the CAFs [38,115], which could be part of the reason why elevated levels of
VEGF are found in cancerous tissues but not the benign tissues [116]. One of the effects of
VEGF is to support tumor neovascularization through the secretion of proteolytic enzymes
to dismantle the ECM, which favors EMT [116]. The precise mechanism for VEGF-mediated
prostate cancer metastasis is not yet completely understood. But it has been hypothesized
that the bone stroma-secreted VEGF interacts with cancer cells’ VEGFR and subsequently
enhances cancer cells nesting to the bone [116]. This hypothesis is supported by the fact that
elevated levels of VEGFR-2 were consistently found on prostate cancer cells [117]. More
importantly, both VEGF and VEGFR-2 are notably higher at the sites of bone metastasis
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than at the primary prostate tumors of the same individual, further demonstrating the
importance of the VEGF/VEGFR-2 axis in prostate cancer bone metastasis [117]. Interestingly, RSV and its analog HS-1793 are capable of inhibiting both hypoxia-induced VEGF
expression and prostate cancer cell migration [115] (Figure 3). In addition, RSV, either
alone or in combination with tumor necrosis factor-related apoptosis-inducing ligand
(TRAIL), can inhibit the VEGF/VEGFR2 axis in vivo [104]. RSV’s inhibitory effect in bone
stroma–prostate cancer cell communication is an ongoing research topic [116–118].
4.4. RSV Inhibits Immune Cell-Mediated Prostate Cancer Metastasis
Although the origin of tumor-associated macrophages is not completely known,
different immune cells, especially the macrophages, are found ubiquitously in solid tumors.
One school of thought is that they are tissue-resident macrophages, and another postulates
that the tumor macrophages are derived from monocytes [80,119]. Nevertheless, it is widely
accepted that immune cells not only exist in the TME but also affect the development of
prostate cancer, and multiple lines of evidence indicate that RSV is capable of inhibiting the
immune cell–mediated prostate cancer metastasis. Based on the number of macrophages
found in prostate cancer tissues derived from different patients, Lewis and colleagues
concluded that macrophages could lead to either favorable or unfavorable prognosis in
prostate cancer [120]. Later, it was found that higher tumor-associated macrophage (TAM)
count is correlated with a reduced survival time but an increased disease-free survival after
treatment [121,122]. The authors attribute this inconsistency to not only the methodological
differences between studies but also the complex functions of macrophages.
While direct evidence of RSV’s effects on macrophage activity in prostate cancer is
limited, evidence of RSV’s effects on macrophages in other cancers is well documented.
Based on their roles in tumor development, the macrophages in the tumor tissues can
be divided into either M1- or M2-like subtypes. The M1-like macrophages possess an
antitumor property by promoting Th1 response, and the M2-like macrophages usually
promote Th2 response, tissue remodeling, immune tolerance, and tumor progression [123].
TAMs are phenotypically similar to M2 macrophages [124]. Recently, Kimura et al. experimentally demonstrated that RSV can prevent tumor cell metastasis by inhibiting M2-like
macrophage differentiation [125]. Consistent with the findings that prostate cancer can
secret certain factors, including IL-10, to induce M2 polarization [126], the authors further
demonstrated that RSV is capable of inhibiting M2 differentiation by downregulating
IL-10 secretion. Finally, oral administration of RSV (25 mg/kg, twice daily) for 30 days to
mice injected with the highly metastatic osteosarcoma LM8 cells significantly reduced the
number of metastatic tumors in both the lungs and the liver. These in vitro and in vivo data
altogether unambiguously demonstrate that RSV is indeed capable of inhibiting cancer cell
metastasis. However, whether RVS has a similar effect on prostate cancer cell metastasis
still needs to be determined experimentally.
5. Conclusions and Perspectives
Since its anti-inflammation and anti-oxidation activities were demonstrated experimentally in 1997 [22], RSV and its derivatives have attracted great attention in both basic
science and clinical settings. Because of its beneficial effects on improved metabolism, cardio protection, and cancer prevention, RSV has even been widely accepted as an anti-aging
reagent. The general beneficial effects of RSV on many diseases have been thoroughly reviewed by Baur and Sinclair [23]. Discussion of clinical literature, along with the limitations
of preclinical and in vitro RSV studies, can be found in the review article by Tome-Carneiro
et al. [127]. The in vivo effects of resveratrol on different cancers, including breast, colorectal, liver, pancreatic, and prostate cancer have been systematically reviewed by Lindsay G.
Carter [128]. More importantly, data from both in vitro and in vivo experiments indicate
that RSV is one of a few natural products with minimal adverse effects. These findings
make RSV an ideal preventive and therapeutic reagent.
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Because of the ubiquitous role of the androgen/AR axis in each process of prostate
cancer development, including initiation, progression, and metastasis, special attention
has been paid to the effects of RSV on AR. Relatively little attention has been paid to the
RSV effect on epithelium–stroma interaction, although it is well known that RSV can exert
its effects on prostate cancer in an AR-independent manner [129]. RSV has differential
effects on growth, cell cycle arrest, and induction of apoptosis by RSV in human prostate
cancer cell lines [130,131]. Overwhelming evidence suggests that RSV’s anti-prostate
cancer effect is through targeting the AR and subsequent AR-regulated genes [50,132,133].
Harada et al. reported that RSV represses AR target gene expression, at least partially,
by enhancing AR degradation in a time- and dose-dependent manner [134]. Along with
other groups, we have demonstrated that RSV can repress AR function by inhibiting
AR transcriptional activity [135]. In addition, a group of ~20 AR variants (ARVs) has
been identified in prostate cancer, especially the metastatic castration-resistant prostate
cancer (mCRPC). Among these variants, ARV7 has attracted special attention because
of its androgen-independent transcriptional activity [136]. More recent findings suggest
that approximately 10–30% of men with mCRPC are positive for AR-V7 [137]. We have
also demonstrated that RSV is capable of repressing mCRPC cell growth by enhancing
ARV7 poly-ubiquitination and subsequent degradation [138]. These findings suggest that
resveratrol could be used as a prostate cancer preventive or therapeutic reagent.
Given the emerging roles of the stromal cells in cancer initiation and progression,
great attention has been paid to the communication between stromal and cancer cells
in recent years. Mounting evidence indicates that the stromal cells play indispensable
roles in prostate cancer initiation, proliferation, and metastasis. As we have discussed
in this review, by interrupting the epithelial and stromal cell communication, RSV can
inhibit prostate cancer development through different mechanisms. However, there are still
many unanswered questions about how RSV affects stromal–cancer cell communication.
For example, it is well established that AR is expressed and functional in both epithelial
and stromal cells [11]. But compared to our understanding of RSV’s effect on epithelial
cells, very little is known about the role of RSV in stromal cells. Besides, ARV7 plays an
indispensable role in mCRPC, and resveratrol can inhibit the proliferation of AVR7-positive
cells. Our unpublished data indicate that RSV can affect the E-cadherin and N-cadherin
ratio in ARV7-positive prostate cancer cells, suggesting that RSV could potentially be able
to affect the metastasis of these cells. Whether ARV7 is simultaneously or subsequently
expressed in cancer and stromal cells is unknown. If ARV7 is indeed expressed in stromal
cells, will RSV also affect the stromal cells through targeting ARV7 as it did in the cancer
cells? Answers to these questions and a better understanding of the underlying molecular
mechanisms in how RSV inhibits prostate cancer progression by interrupting stromal–
cancer cell communication will pave the road toward the application of RSV as both a
cancer preventive and therapeutic reagent.
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